medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2019, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2019; 66 (1)

Correlation among two methods for glycated hemoglobin determination in diabetic Mexican patients for glycemic control

Gastélum-Cano JM, García-Alcalá H, Rodríguez-Gallegos AB, Fragoso-Flores J, Vera-Balderas AM

Language: English
References: 35
Page: 13-19
PDF size: 252.10 Kb.


ABSTRACT

Glycated hemoglobin (HbA1c) is a molecule derived from the non-enzymatic union of glucose in the β chain of Hemoglobin (Hb) A of red blood cells proposed for the American Diabetes Association (ADA) as the best test to evaluate long term glycemic control. The precision in its determination is a very important issue. The objective of this study was to analyze correlation and to determine glycemic control classification concordance among two methods : Ion-Exchange High-performance Liquid Chromatography (IE-HPLC) and Capillary Electrophoresis (CE) using two commercial instruments. A total of 249 samples from diabetic patients (n) were tested for HbA1c by both methods. Results were analyzed by correlation, Bland-Altman scatter plots and calculating CE’s sensitivity (Sn), specificity (Sp), positive and negative predictive values (PPV and NPV) to identify glycemic control (HPLC HbA1c ‹ 7%). The correlation was statistically significant (r = 0.9906, p ‹ 0.0001), Kappa correlation 0.959 (p ‹ 0.05); Bland-Altman plot analysis showed high level of agreement. CE Sn, SP, PPV and NPV were respectively: 98%, 98, 99% and 97%. Considerable differences in glycemic control classification were not observed. CE in Capillarys 2FP seems to be a good alternative method for HbA1c measuring for glycemic control.


REFERENCES

  1. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41: S13-S27. doi: 10.2337/dc18-S002.

  2. Bhattacharya S, Dey D, Roy SS. Molecular mechanism of insulin resistance. J Biosci. 2007. doi: 10.1007/s12038-007-0038-8.

  3. Zick Y. Insulin resistance: A phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol. 2001. doi: 10.1016/S0962-8924(01)02129-8.

  4. Paz K, Hemi R, LeRoith D et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 1997. doi: 10.1074/jbc.272.47.29911.

  5. American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. J Clin Appl Res Educ. 2018; 41 (Supplement 1): S1-S159. doi: 10.2337/dc13-S011.

  6. Vijan S. Type 2 diabetes. Ann Intern Med. 2010. doi: 10.7326/0003-4819-152-5-201003020-01003.

  7. Gutiérrez JP, Rivera-Dommarco JA, Shamah-Levy T et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. 2a. ed. Inst Nac Salud Publica. 2013. doi: 10.4206/agrosur.1974.v2n2-09.

  8. Herrington WG, Alegre-Díaz J, Wade R et al. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diabetes Endocrinol. 2018; 6 (6): 455-463. doi: 10.1016/S2213-8587(18)30050-0.

  9. Sattar N, Preiss D. HbA1cin type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetología. 2012; 55 (6): 1564-1567. doi: 10.1007/s00125-012-2510-8.

  10. Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem. 1980; 255 (7): 3120-3127.

  11. Penttilä I, Penttilä K, Holm P et al. Methods, units and quality requirements for the analysis of haemoglobin A 1c in diabetes mellitus. World J Methodol. 2016; 6 (2): 133. doi: 10.5662/wjm.v6.i2.133.

  12. Jeppsson J-O, Kobold U, Barr J et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002; 40 (1): 78-89. doi: 10.1515/CCLM.2002.016.

  13. Rhea JM, Molinaro R. Pathology consultation on HbA1c methods and interferences. Am J Clin Pathol. 2014; 141 (1): 5-16. doi: 10.1309/AJCPQ23GTTMLAEVL.

  14. Herpol M, Lanckmans K, Van Neyghem S et al. Evaluation of the Sebia Capillarys 3 Tera and the Bio-Rad D-100 systems for the measurement of hemoglobin A1c. Am J Clin Pathol. 2016; 146 (1): 67-77. doi: 10.1093/ajcp/aqw081.

  15. Dessi M, Pieri M, Pignalosa S, Martino FG, Zenobi R. Performances of capillary electrophoresis and HPLC methods in HbA1c determination: diagnostic accuracy in HbS and HbD-Iran variants’ presence. J Clin Lab Anal. 2015; 29 (1): 57-60. doi: 10.1002/jcla.21728.

  16. Klingenberg O, Furuset T, Hestbråten CR et al. HbA1c analysis by capillary electrophoresis–comparison with chromatography and an immunological method. Scand J Clin Lab Invest. 2017; 77 (6): 458-464. doi: 10.1080/00365513.2017.1338747.

  17. Wu X, Chao Y, Wan Z et al. A comparative evaluation of the analytical performances of Capillarys 2 flex piercing, tosoh HLC-723 G8, premier Hb9210, and roche cobas c501 tina-quant gen 2 analyzers for HbA1cdetermination. Biochem Medica. 2016; 26 (3): 353-364. doi: 10.11613/BM.2016.039.

  18. Lin CN, Emery TJ, Little RR, et al. Effects of hemoglobin C, D, E, and S traits on measurements of HbA 1c by six methods. Clin Chim Acta. 2012; 413 (7-8): 819-821. doi: 10.1016/j.cca.2011.12.019.

  19. Urrechaga E. High-resolution HbA 1c separation and hemoglobinopathy detection with capillary electrophoresis. Am J Clin Pathol. 2012; 138 (3): 448-456. doi: 10.1309/AJCPVYW9QZ9EVFXI.

  20. Cobián JG, Sánchez-López JY, Magaña MT, Chávez ML, Perea FJ, Ibarra B. Types and frequencies of hemoglobin disorders in the pacific coast of four states of Mexico. Rev Investig Clin. 2009.

  21. Ruiz-Reyes G. Abnormal hemoglobins and thalassemias in Mexico. Rev Invest Clin. 1998.

  22. National Glycohemoglobin Standardization Program (NGSP). HbA1c Assay Interferences. [Accessed 5 November 2018] http://www.ngsp.org/interf.asp.

  23. Chandrashekar V. Hb A1c Separation by high performance liquid chromatography in hemoglobinopathies. Scientifica (Cairo). 2016; 2016: 1-5. doi: 10.1155/2016/2698362.

  24. Little RR, La’Ulu SL, Hanson SE, Rohlfing CL, Schmidt RL. Effects of 49 different rare Hb variants on HbA1c measurement in eight methods. J Diabetes Sci Technol. 2015; 9 (4): 849-856. doi: 10.1177/1932296815572367.

  25. Gupta M, Datta P, Rao P. Haemoglobin hope: a rare Hb variant causing spuriously elevated HbA1c Values on HPLC Assay. 2016: 1-3. doi: 10.7860/NJLM/2016/14873.

  26. Chakraborty S, Chanda D, Gain M, Krishnan P. Interference of the hope hemoglobin with hemoglobin A1c results. Lab Med. 2015; 46 (3): 221-225. doi: 10.1309/LME82XNY6SYVWDYQ.

  27. Dimeski G, Pretorius CJ, Russell AW, Miller SP, Bird RJ, Ungerer JPJ. A case of discordant HbA1c: A method-dependent error. Med J Aust. 2009; 191 (6): 347-349. doi: dim10266_fm [pii].

  28. Kim, Jong Taek Winter E. William, Hong-yuan Luo, Chui David HN. Interference of hemoglobin A1c due to hemoglobin franklin park. J Appl Lab Med. 2018; 03 (05): 1-3.

  29. Sebia. Capillarys Hb A1c Using the Capillarys 2 flex-piercing instrument.

  30. Jaisson S, Leroy N, Meurice J. First evaluation of Capillarys 2 Flex Piercing® (Sebia) as a new analyzer for HbA1c assay by Capillary electrophoresis. Clin Chem Lab Med. 2012; 50 (10): 1769-1775. doi: 10.1515/cclm-2012-0017.

  31. Baroncini D, Zaffaroni M, Moiola L et al. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Mult Scler J. 2018: 1-9. doi: 10.1177/1352458518754364.

  32. Urrechaga E. High-resolution HbA1cseparation and hemoglobinopathy detection with capillary electrophoresis. Am J Clin Pathol. 2012; 138 (3): 448-456. doi:10.1309/AJCPVYW9QZ9EVFXI.

  33. Food and Drugs Administration. Decision Memorandum Assay and Instrument Combination Template k161681. [Accessed January 19, 2019] https://www.accessdata.fda.gov/cdrh_docs/reviews/K161687.pdf.

  34. Marzullo C, Minery M. abc Évaluation de l’analyseur D10® pour le dosage. 2008; 66 (1): 95-99.

  35. Food and Drugs Administration. Decision Memorandum Assay and Instrument Combination Template k171861. [Accessed January 19, 2019] https://www.accessdata.fda.gov/cdrh_docs/reviews/K171861.pdf.




2020     |     www.medigraphic.com